The present invention includes compositions and methods for the treatment of cancer comprising an antineoplastic drug and an inhibitor of chromosome maintenance region 1 (CRM1) protein expression or activity, wherein the inhibitor of CRM1 enhances the anti-neoplastic effect of the antineoplastic drug.